We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.


Sartorius Acquires US Start-up ViroCyt

By Labmedica International staff writers
Posted on 22 Jul 2016
Sartorius AG (Göttingen, Germany), a pharmaceutical and laboratory equipment provider, has acquired ViroCyt Incorporated (Broomfield, CO, USA), a start-up in the field of rapid virus quantification, in a deal valued at approximately USD 16 million.

ViroCyt’s automated platform integrates instruments, software and reagents to deliver faster results in comparison to commonly used methods for virus counting. The company’s key customers include pharma and biopharma R&D laboratories, vaccine manufacturers and academic institutes focused on virology.

In June this year, Sartorius had acquired IntelliCyt Corporation (Albuquerque, NM, USA) a manufacturer of cell screening platforms used in drug discovery, for USD 90 million in cash. The acquisition was a part of Sartorius’ efforts to expand its current lab portfolio into bio analytics, thereby strengthening its offering for the company’s biopharma customers and academia.

Michael Melingo, member of the Sartorius Group Executive Committee, said, “After acquiring the cell screening specialist IntelliCyt, we are now adding a further very innovative bioanalytical tool to our Lab Products & Services portfolio that will enable our customers to obtain lab results much faster and reduce the time to clinic for virus-based pharmaceuticals.”

“Sartorius is an ideal partner for us due to its global presence and strong reputation for innovation and quality. By joining forces, we will drive further adoption of our novel approach to virus quantification both in the US and in international markets,” said Robert Kline, President and CEO of ViroCyt.

Related Links:

Latest BioResearch News